<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899118</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH-ARO2013</org_study_id>
    <nct_id>NCT01899118</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a&#xD;
      standard treatment of locally advanced rectal adenocarcinomas, which correlates better local&#xD;
      control and higher sphincter preservation rate. Nimotuzumab, a humanized monoclonal antibody&#xD;
      against epidermal growth factor receptor (EGFR) has been reported to improve the therapeutic&#xD;
      effect of radiotherapy in some cancers. This study is a clinical phase II trial designed to&#xD;
      evaluate the efficacy of the combination of Nimotuzumab administered concurrently with&#xD;
      neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, and to further&#xD;
      investigate its side-effect and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathology complete remission rate</measure>
    <time_frame>1 year</time_frame>
    <description>Pathology complete remission rate is the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor regression rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sphincter preservation rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>up to 1 month after the last cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative irradiation</intervention_name>
    <description>50.4Gy/28F/5.5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg/w，0-5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130mg/m2 d1</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825mg/m2 bid d1-5/w,1-5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Age:18-75 years&#xD;
&#xD;
          3. Histologically confirmed locally advanced colorectal cancer (adenocarcinoma)&#xD;
&#xD;
          4. The lower edge of the tumors located below 12 cm from the anal verge&#xD;
&#xD;
          5. Karnofsky Performance Scale ≥70 points, Life expectancy ≥ 6 months&#xD;
&#xD;
          6. No prior chemotherapy was used&#xD;
&#xD;
          7. No history of regional radiation treatment inthe pelvic cavity&#xD;
&#xD;
          8. Adequate hematologic function: Hb ≥ 100 g/L , WBC≥3.5×109, ANC ≥ 1.5×109 /L，PLT ≥&#xD;
             100×109 /L Adequate renal function: Cr ≤ 1.5×ULN, TB≤2.5 × ULN Adequate hepatic&#xD;
             function: ALT/AST ≤ 2.5×ULN, Alkaline phosphatase ≤ 2.5×ULN&#xD;
&#xD;
          9. Patients without peripheral neuropathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in&#xD;
             situ&#xD;
&#xD;
          2. Rectal cancer patients with concurrent colon cancer&#xD;
&#xD;
          3. Pregnant or lactating women&#xD;
&#xD;
          4. Fertile female patients without using any contraceptives&#xD;
&#xD;
          5. Allergic to cisplatin and fluorouracil&#xD;
&#xD;
          6. Patients with previous peripheral neuropathy&#xD;
&#xD;
          7. Serious complications: myocardial infarction, heart failure (NYHA Classification&gt;II&#xD;
             grade),psychiatric history and severe diabetes&#xD;
&#xD;
          8. Treatment with other anti-cancer therapy(including Chinese herbal medicine)&#xD;
&#xD;
          9. Organ transplant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Luo, MD</last_name>
      <phone>0086-571-88122062</phone>
    </contact>
    <investigator>
      <last_name>Yuan Zhu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>Neoadjuvant chemoradiotherapy</keyword>
  <keyword>Nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

